Amicogen Inc
KOSDAQ:092040
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Amicogen Inc
Income from Continuing Operations
Amicogen Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Amicogen Inc
KOSDAQ:092040
|
Income from Continuing Operations
-₩30.4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Income from Continuing Operations
₩1T
|
CAGR 3-Years
25%
|
CAGR 5-Years
14%
|
CAGR 10-Years
22%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Income from Continuing Operations
-₩15.7B
|
CAGR 3-Years
18%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Income from Continuing Operations
-₩32.6B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Income from Continuing Operations
₩145.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
61%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Income from Continuing Operations
-₩37.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
Amicogen Inc
Glance View
Amicogen, Inc. engages in the development and sale of enzyme products and functional food materials. The company is headquartered in Jinju, Gyeongsangnam-Do. The company went IPO on 2013-09-12. The Company’s products consist of special enzymes, N-acetylglucosamine (NAG), pinitol, D-Chiro-inositol (DCI), collagen peptides (CP) and protein A chromatography resins. The firm distributes its products within domestic market and to overseas markets, including China, Japan, the United Sates, Germany and Thailand.
See Also
What is Amicogen Inc's Income from Continuing Operations?
Income from Continuing Operations
-30.4B
KRW
Based on the financial report for Dec 31, 2025, Amicogen Inc's Income from Continuing Operations amounts to -30.4B KRW.
What is Amicogen Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
13%
Over the last year, the Income from Continuing Operations growth was 40%. The average annual Income from Continuing Operations growth rates for Amicogen Inc have been 13% over the past three years .
